Pohjois-Pohjanmaan hyvinvointialue

The medical center is at the forefront of pediatric neuro-oncology, focusing on the diagnosis and treatment of ependymoma in children, adolescents, and young adults. The center's research aims to enhance the assessment of residual disease through centralized reviews of post-operative MRI, potentially increasing complete resection rates.

• Centralized neurosurgical and radiological review
• Progression-free survival improvement
• Post-operative chemotherapy schedules

By integrating advanced imaging techniques and innovative chemotherapy protocols, the center is pioneering new standards in the treatment of pediatric brain tumors.

Specializing in acute myeloid leukemia (AML) in children, the center is dedicated to improving prognosis through enhanced risk stratification and intensive induction therapies. The research focuses on evaluating the efficacy of novel chemotherapeutic agents and the prognostic impact of minimal residual disease (MRD) measurement.

• Risk stratification based on MRD quantification
• Comparative efficacy of chemotherapeutic agents
• Prognostic impact of MRD measurement

Through these efforts, the center aims to refine treatment protocols and improve survival rates for pediatric AML patients.

The center is engaged in cutting-edge research on high-risk medulloblastoma, exploring advanced radiotherapy techniques and maintenance chemotherapy therapies. The goal is to improve outcomes for patients with this aggressive form of brain cancer.

• Hyperfractionated-accelerated radiotherapy (HART)
• High-dose therapy with thiotepa
• Maintenance chemotherapy strategies

By evaluating these innovative treatment approaches, the center contributes to the development of more effective therapies for high-risk medulloblastoma.

Focusing on advanced ovarian cancer, the center conducts research to assess the efficacy of combining standard chemotherapy with novel agents like durvalumab and olaparib. This research aims to improve progression-free survival in patients with newly diagnosed advanced ovarian cancer.

• Combination therapies with durvalumab and olaparib
• Progression-free survival assessment
• Advanced ovarian cancer treatment strategies

The center's work in this area is pivotal in developing new therapeutic options for ovarian cancer patients.

In the field of idiopathic pulmonary fibrosis (IPF), the center is investigating the potential of BI 1819479 to improve lung function. The research focuses on understanding the dose-response relationship and evaluating the treatment effect size of this novel therapeutic agent.

• Non-flat dose response curve analysis
• Quantitative treatment effect evaluation
• Dose-response relationship studies

Through these studies, the center aims to advance treatment options for patients suffering from IPF.

The center is actively involved in research on high-risk nonmetastatic prostate cancer, evaluating the safety and effectiveness of enzalutamide in combination with leuprolide. This research seeks to determine the most effective treatment regimen for patients progressing after definitive therapy.

• Combination therapy with enzalutamide and leuprolide
• Comparative efficacy studies
• Advanced prostate cancer treatment strategies

By exploring these therapeutic combinations, the center contributes to the development of improved treatment protocols for prostate cancer.